References
- Eichholtz T, Jalink K, Farenfort I, et al. The bioactive phospholipid lysophosphatidic acid is released from activated platelets. Biochem J. 1993;291:677–680.
- Aikawa S, Hashimoto T, Kano K, et al. Lysophosphatidic acid as a lipid mediator with multiple biological actions. J Biochem. 2015;157:81–89.
- Stoddard NC, Chun J. Promising pharmacological directions in the world of lysophosphatidic acid signaling. Biomol Ther. 2015;23:1–11.
- Yung YC, Stoddard NC, Chun J. LPA receptor signaling: pharmacology, physiology, and pathophysiology. J Lipid Res. 2014;55:1192–1214.
- Lin M-E, Herr DR, Chun J. Lysophosphatidic acid (LPA) receptors: Signaling properties and disease relevance. Prostaglandins Other Lipid Mediat. 2010;91:130–138.
- Xu Y, Gaudette DC, Boynton JD, et al. Characterization of an ovarian cancer activating factor in ascites from ovarian cancer patients. Clin Cancer Res. 1995;1:1223–1232.
- Tsujiuchi T, Araki M, Hirane M, et al. Lysophosphatidic acid receptors in cancer pathobiology. Histol Histopathol. 2014;29:313–321.
- Tsujiuchi T, Hirane M, Dong Y, et al. Diverse effects of LPA receptors on cell motile activities of cancer cells. J Recept Signal Transduct Res. 2014;34:201–204.
- Okabe K, Kato K, Teranishi M, et al. Induction of lysophosphatidic acid receptor-3 by 12-O-tetradecanoylphorbol-13-acetate stimulates cell migration of rat liver cells. Cancer Lett. 2011;309:236–242.
- Hirane M, Ishii S, Tomimatsu A, et al. Different induction of LPA receptors by chemical liver carcinogens regulates cellular functions of liver epithelial WB-F344 cells. Mol Carcinog . 2016;55:1573–1583.
- Fukushima K, Takahashi K, Yamasaki E, et al. Lysophosphatidic acid signaling via LPA1 and LPA3 regulates cellular functions during tumor progression in pancreatic cancer cells. Exp Cell Res. 2017;352:139–145.
- Takahashi K, Fukushima K, Onishi Y, et al. Lysophosphatidic acid (LPA) signaling via LPA4 and LPA6 negatively regulates cell motile activities of colon cancer cells. Biochem Biophys Res Commun. 2017;483:625–657.
- Borowicz S, Van Scoyk M, Avasarala S, Karuppusamy Rathinam MK, Tauler J, Bikkavilli RK, Winn RA. The soft agar colony formation assay. J Vis Exp. 2014;27:e51998.
- Chekhun VF, Lukyanova NY, Kovalchuk O, et al. Epigenetic profiling of multidrug-resistant human MCF-7 breast adenocarcinoma cells reveals novel hyper- and hypomethylated targets. Mol Cancer Ther. 2007;6:1089–1098.
- Ishii S, Hirane M, Fukushima K, et al. Diverse effects of LPA4, LPA5, and LPA6 on the activation of tumor progression in pancreatic cancer cells. Biochem Biophys Res Commun. 2015;461:59–64.
- Tsujino M, Fujii M, Okabe K, et al. Differential expressions and DNA methylation patterns of lysophosphatidic acid receptor genes in human colon cancer cells. Virchows Arch. 2010;457:669–676.
- Shano S, Hatanaka K, Ninose S, et al. A lysophosphatidic acid receptor lacking the PDZ-binding domain is constitutively active and stimulates cell proliferation. Biochim Biophys Acta. 2008;1783:748–759.
- Hayashi M, Okabe K, Kato K, et al. Differential function of lysophosphatidic acid receptors in cell proliferation and migration of neuroblastoma cells. Cancer Lett. 2012;316:91–96.
- Takahashi K, Fukushima K, Fukushima N, et al. Enhanced cellular functions through induction of LPA2 by cisplatin in fibrosarcoma HT1080 cells. Mol Cell Biochem. 2017;431:29–35.
- Fischer DJ, Nusser N, Virag T, et al. Short-chain phosphatidates are subtype-selective antagonists of lysophosphatidic acid receptors. Mol Pharmacol. 2001;60:776–784.